uniQure N.V. (0EE0.L)

USD 14.96

(-0.33%)

Operating Expenses Summary of uniQure N.V.

  • uniQure N.V.'s latest annual operating expenses in 2023 was 285.08 Million USD , up 15.75% from previous year.
  • uniQure N.V.'s latest quarterly operating expenses in 2024 Q3 was 42.17 Million USD , down -14.25% from previous quarter.
  • uniQure N.V. reported a annual operating expenses of 246.29 Million USD in annual operating expenses 2022, up 30.73% from previous year.
  • uniQure N.V. reported a annual operating expenses of 188.4 Million USD in annual operating expenses 2021, up 15.63% from previous year.
  • uniQure N.V. reported a quarterly operating expenses of 51.99 Million USD for 2024 Q1, down -12.77% from previous quarter.
  • uniQure N.V. reported a quarterly operating expenses of 48.39 Million USD for 2024 Q2, down -6.93% from previous quarter.

Annual Operating Expenses Chart of uniQure N.V. (2023 - 2011)

Historical Annual Operating Expenses of uniQure N.V. (2023 - 2011)

Year Operating Expenses Operating Expenses Growth
2023 285.08 Million USD 15.75%
2022 246.29 Million USD 30.73%
2021 188.4 Million USD 15.63%
2020 162.94 Million USD 26.88%
2019 128.42 Million USD 29.05%
2018 99.51 Million USD 16.99%
2017 85.06 Million USD -12.34%
2016 97.04 Million USD 35.23%
2015 71.76 Million USD 53.21%
2014 46.83 Million USD 37.45%
2013 34.07 Million USD 81.57%
2012 18.76 Million USD -15.52%
2011 22.21 Million USD 0.0%

Peer Operating Expenses Comparison of uniQure N.V.

Name Operating Expenses Operating Expenses Difference
Abeona Therapeutics Inc. 48.5 Million USD -487.782%
Aclaris Therapeutics, Inc. 12.14 Million USD -2248.126%
Agios Pharmaceuticals, Inc. 408.8 Million USD 30.264%
Atara Biotherapeutics, Inc. 275.69 Million USD -3.407%
Cara Therapeutics, Inc. 142.46 Million USD -100.112%
Imunon, Inc. 21.03 Million USD -1255.588%
Dynavax Technologies Corporation 219.14 Million USD -30.09%
Editas Medicine, Inc. 247.3 Million USD -15.278%
FibroGen, Inc. 398.11 Million USD 28.391%
Iovance Biotherapeutics, Inc. 450.99 Million USD 36.787%
Kala Pharmaceuticals, Inc. 39.15 Million USD -628.133%
Neurocrine Biosciences, Inc. 1.59 Billion USD 82.143%
Sarepta Therapeutics, Inc. 1.36 Billion USD 79.05%
Supernus Pharmaceuticals, Inc. 529.01 Million USD 46.11%
Verastem, Inc. 92.08 Million USD -209.593%
Zoetis Inc. 2.76 Billion USD 89.689%
Vertex Pharmaceuticals Incorporated 4.77 Billion USD 94.03%
Sangamo Therapeutics, Inc. 228.68 Million USD -24.666%
Homology Medicines, Inc. 9.87 Million USD -2786.947%
Nektar Therapeutics 190.9 Million USD -49.336%
Viking Therapeutics, Inc. 100.82 Million USD -182.748%
Unity Biotechnology, Inc. 44.66 Million USD -538.247%
Perrigo Company plc 1.52 Billion USD 81.349%
Esperion Therapeutics, Inc. 271.89 Million USD -4.851%
Walgreens Boots Alliance, Inc. 40.6 Billion USD 99.298%
Illumina, Inc. 3.81 Billion USD 92.523%
Thermo Fisher Scientific Inc. 10.25 Billion USD 97.22%
IQVIA Holdings Inc. 2.05 Billion USD 86.114%
Heron Therapeutics, Inc. 120.65 Million USD -136.278%
Waters Corporation 943.51 Million USD 69.785%
Biogen Inc. 5.2 Billion USD 94.523%
Evolus, Inc. 189.75 Million USD -50.236%
Adicet Bio, Inc. 152.03 Million USD -87.51%
bluebird bio, Inc. 240.23 Million USD -18.671%
Geron Corporation 70.44 Million USD -304.716%
Alnylam Pharmaceuticals, Inc. 1.8 Billion USD 84.162%
Amicus Therapeutics, Inc. 427.65 Million USD 33.337%
Myriad Genetics, Inc. 600.1 Million USD 52.494%
Intellia Therapeutics, Inc. 551.56 Million USD 48.313%
Mettler-Toledo International Inc. 1.08 Billion USD 73.831%
Corbus Pharmaceuticals Holdings, Inc. 13.9 Million USD -1949.557%
BioMarin Pharmaceutical Inc. 1.74 Billion USD 83.675%
Regeneron Pharmaceuticals, Inc. 2.81 Billion USD 89.874%
Agilent Technologies, Inc. 2.11 Billion USD 86.521%
OPKO Health, Inc. 574.68 Million USD 50.393%
Exelixis, Inc. 1.58 Billion USD 82.034%
Corcept Therapeutics Incorporated 368.61 Million USD 22.66%
Anavex Life Sciences Corp. 55.75 Million USD -411.31%
Axsome Therapeutics, Inc. 476.36 Million USD 40.153%
Ionis Pharmaceuticals, Inc. 779.58 Million USD 63.431%
Halozyme Therapeutics, Inc. 299.31 Million USD 4.755%
Blueprint Medicines Corporation 722.86 Million USD 60.561%
Insmed Incorporated 949.26 Million USD 69.968%
TG Therapeutics, Inc. 198.47 Million USD -43.638%
Incyte Corporation 1.19 Billion USD 76.053%
Emergent BioSolutions Inc. 1.04 Billion USD 72.693%